on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Begins Trading on Nasdaq Following Merger
Aspire Biopharma, Inc., a developer of innovative drug delivery technologies, announced its public listing on the Nasdaq Global Market. This follows the completion of its business merger with PowerUp Acquisition Corp., a special purpose acquisition company. The merger was finalized on February 17, 2025, after gaining approval from PowerUp's shareholders in January.
Starting February 20, 2025, Aspire's common stock and warrants will be traded on Nasdaq under the symbols "ASBP" and "ASBPW". This development is poised to enhance Aspire's access to capital and foster its internal development and strategic partnerships.
The merger provides Aspire with a boost in resources to accelerate the development of their fast-absorbing aspirin, which aims for fast-track approval from the FDA to combat cardiac incidents.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news